Scholarlink

Objectives <p>To develop and validate an interpretable CT-based vision transformer (ViT) model for preoperative prediction of the stage, size, grade, and necrosis (SSIGN) and outcome in clear cell renal cell carcinoma (ccRCC) patients.</p> Methods <p>Eight hundred forty-five ccRCC patients from multiple centers were retrospectively enrolled. For each patient, 768 ViT features were extracted in the cortical medullary phase (CMP) and renal parenchymal phase (RPP) images, respectively. The CMP ViT model (CVM), RPP ViT model (RVM), and CMP-RPP combined ViT model (CRVM) were constructed to predict the SSIGN in ccRCC patients. The area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of each model. Decision curve analysis (DCA) was used to evaluate the net clinical benefit. The endpoint was the progression-free survival (PFS). Kaplan–Meier survival analysis was used to assess the association between model-predicted SSIGN and PFS. The SHAP approach was applied to determine the prediction process of the CRVM.</p> Results <p>The CVM, RVM, and CRVM demonstrated good performance in predicting SSIGN, with a high AUC of 0.859, 0.883, and 0.895, respectively, in the test cohort. DCA demonstrated the CRVM performed best in clinical net benefit. In predicting PFS, CRVM achieved a higher Harrell’s concordance index (<i>C</i>-index, 0.840) than the CVM (0.719) and RVM (0.773) in the test cohort. The SHAP helped us understand the impact of ViT features on CRVM’s SSIGN prediction from a global and individual perspective.</p> Conclusion <p>The interpretable CT-based CRVM may serve as a non-invasive biomarker in predicting the SSIGN and outcome of ccRCC.</p> Critical relevance statement <p>Our findings outline the potential of an interpretable CT-based ViT biomarker for predicting the SSIGN score and outcome of ccRCC, which might facilitate patient counseling and assist clinicians in therapy decision-making for individual cases.</p> Key Points <p><UnorderedList Mark="Bullet"> <ItemContent> <p>Current first-line imaging lacks preoperative prediction of the SSIGN score for ccRCC patients.</p> </ItemContent> <ItemContent> <p>The ViT model could predict the SSIGN score and outcome of ccRCC patients.</p> </ItemContent> <ItemContent> <p>This study can facilitate the development of personalized treatment for ccRCC patients.</p> </ItemContent> </UnorderedList></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The interpretable CT-based vision transformer model for preoperative prediction of clear cell renal cell carcinoma SSIGN score and outcome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月9日

查看全文
  • Kaiyue Zhi,
  • Yanmei Wang,
  • Lei Yan,
  • Feng Hou,
  • Jie Wu,
  • Shuo Zhang,
  • He Zhu,
  • Lianzi Zhao,
  • Ning Wang,
  • Xia Zhao,
  • Xianjun Li,
  • Yicong Wang,
  • Chengcheng Chen,
  • Nan Wang,
  • Yuchao Xu,
  • Guangjie Yang,
  • Pei Nie

摘要

Objectives

To develop and validate an interpretable CT-based vision transformer (ViT) model for preoperative prediction of the stage, size, grade, and necrosis (SSIGN) and outcome in clear cell renal cell carcinoma (ccRCC) patients.

Methods

Eight hundred forty-five ccRCC patients from multiple centers were retrospectively enrolled. For each patient, 768 ViT features were extracted in the cortical medullary phase (CMP) and renal parenchymal phase (RPP) images, respectively. The CMP ViT model (CVM), RPP ViT model (RVM), and CMP-RPP combined ViT model (CRVM) were constructed to predict the SSIGN in ccRCC patients. The area under the receiver operating characteristic curve (AUC) was used to evaluate the performance of each model. Decision curve analysis (DCA) was used to evaluate the net clinical benefit. The endpoint was the progression-free survival (PFS). Kaplan–Meier survival analysis was used to assess the association between model-predicted SSIGN and PFS. The SHAP approach was applied to determine the prediction process of the CRVM.

Results

The CVM, RVM, and CRVM demonstrated good performance in predicting SSIGN, with a high AUC of 0.859, 0.883, and 0.895, respectively, in the test cohort. DCA demonstrated the CRVM performed best in clinical net benefit. In predicting PFS, CRVM achieved a higher Harrell’s concordance index (C-index, 0.840) than the CVM (0.719) and RVM (0.773) in the test cohort. The SHAP helped us understand the impact of ViT features on CRVM’s SSIGN prediction from a global and individual perspective.

Conclusion

The interpretable CT-based CRVM may serve as a non-invasive biomarker in predicting the SSIGN and outcome of ccRCC.

Critical relevance statement

Our findings outline the potential of an interpretable CT-based ViT biomarker for predicting the SSIGN score and outcome of ccRCC, which might facilitate patient counseling and assist clinicians in therapy decision-making for individual cases.

Key Points

Current first-line imaging lacks preoperative prediction of the SSIGN score for ccRCC patients.

The ViT model could predict the SSIGN score and outcome of ccRCC patients.

This study can facilitate the development of personalized treatment for ccRCC patients.

Graphical Abstract